A randomized trial of botulinum toxin A for treatment of drooling

Neurology. 2003 Nov 11;61(9):1279-81. doi: 10.1212/wnl.61.9.1279.

Abstract

The authors compared the efficacy of three different doses (18.75, 37.5, and 75 MU per parotid gland) of botulinum toxin A (BTX-A; Dysport, Ipsen Pharma, Germany) injections vs vehicle in patients with sialorrhea (n = 32) using a single-center, prospective, double-blind, placebo-controlled dose-finding study. The primary endpoint was achieved with 75 MU BTX-A without treatment-related adverse events, suggesting BTX-A is a safe and effective treatment for patients with sialorrhea.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Botulinum Toxins, Type A / therapeutic use*
  • Disease Progression
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Female
  • Humans
  • Injections
  • Male
  • Motor Neuron Disease / complications
  • Neuromuscular Agents / therapeutic use
  • Parkinson Disease / complications
  • Parotid Gland / drug effects
  • Prospective Studies
  • Sialorrhea / drug therapy*
  • Sialorrhea / etiology
  • Treatment Outcome

Substances

  • Neuromuscular Agents
  • Botulinum Toxins, Type A